Wisconsin Capital Management LLC Sells 2,018 Shares of Eli Lilly and Company $LLY

Wisconsin Capital Management LLC trimmed its holdings in Eli Lilly and Company (NYSE:LLY) by 28.4% in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 5,077 shares of the company’s stock after selling 2,018 shares during the quarter. Eli Lilly and Company comprises 2.0% of Wisconsin Capital Management LLC’s portfolio, making the stock its 17th biggest holding. Wisconsin Capital Management LLC’s holdings in Eli Lilly and Company were worth $3,874,000 as of its most recent SEC filing.

A number of other hedge funds have also recently added to or reduced their stakes in the stock. Vanguard Group Inc. raised its stake in shares of Eli Lilly and Company by 0.7% in the third quarter. Vanguard Group Inc. now owns 80,959,089 shares of the company’s stock worth $61,771,785,000 after acquiring an additional 551,659 shares during the last quarter. Laurel Wealth Advisors LLC increased its holdings in shares of Eli Lilly and Company by 78,621.2% in the second quarter. Laurel Wealth Advisors LLC now owns 11,552,336 shares of the company’s stock valued at $9,005,392,000 after purchasing an additional 11,537,661 shares in the last quarter. Norges Bank bought a new position in Eli Lilly and Company in the 2nd quarter worth approximately $8,827,714,000. Charles Schwab Investment Management Inc. lifted its holdings in Eli Lilly and Company by 2.0% during the 2nd quarter. Charles Schwab Investment Management Inc. now owns 5,359,653 shares of the company’s stock worth $4,178,010,000 after buying an additional 103,119 shares in the last quarter. Finally, Franklin Resources Inc. boosted its position in Eli Lilly and Company by 13.4% in the 2nd quarter. Franklin Resources Inc. now owns 4,766,865 shares of the company’s stock valued at $3,715,913,000 after buying an additional 564,736 shares during the last quarter. Institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Stock Performance

Shares of LLY opened at $1,007.37 on Wednesday. The company has a debt-to-equity ratio of 1.54, a quick ratio of 1.19 and a current ratio of 1.58. Eli Lilly and Company has a twelve month low of $623.78 and a twelve month high of $1,133.95. The firm’s 50 day moving average price is $1,050.71 and its two-hundred day moving average price is $936.44. The firm has a market cap of $950.31 billion, a P/E ratio of 43.89, a PEG ratio of 1.18 and a beta of 0.40.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings data on Wednesday, February 4th. The company reported $7.54 earnings per share (EPS) for the quarter, topping the consensus estimate of $7.48 by $0.06. Eli Lilly and Company had a net margin of 31.66% and a return on equity of 102.94%. The company had revenue of $19.29 billion during the quarter, compared to the consensus estimate of $17.85 billion. During the same quarter in the prior year, the firm earned $5.32 earnings per share. The firm’s revenue was up 42.6% compared to the same quarter last year. Eli Lilly and Company has set its FY 2026 guidance at 33.500-35.000 EPS. On average, analysts forecast that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Eli Lilly and Company Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, March 10th. Shareholders of record on Friday, February 13th will be paid a $1.73 dividend. The ex-dividend date of this dividend is Friday, February 13th. This represents a $6.92 annualized dividend and a dividend yield of 0.7%. This is a positive change from Eli Lilly and Company’s previous quarterly dividend of $1.50. Eli Lilly and Company’s dividend payout ratio (DPR) is 30.15%.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on LLY shares. Wolfe Research boosted their target price on Eli Lilly and Company from $1,050.00 to $1,250.00 and gave the stock an “outperform” rating in a research report on Wednesday, December 3rd. National Bank Financial set a $1,286.00 price objective on Eli Lilly and Company in a report on Monday, December 1st. Daiwa Securities Group raised their target price on shares of Eli Lilly and Company from $1,230.00 to $1,250.00 and gave the company a “buy” rating in a research note on Wednesday, February 18th. Freedom Capital raised Eli Lilly and Company from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, February 10th. Finally, CICC Research boosted their target price on Eli Lilly and Company from $1,060.00 to $1,107.00 and gave the stock a “neutral” rating in a research report on Wednesday, February 11th. Two analysts have rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and five have assigned a Hold rating to the company’s stock. According to MarketBeat, Eli Lilly and Company currently has an average rating of “Moderate Buy” and an average price target of $1,229.59.

More Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Shareholders of Ventyx Biosciences approved a merger with Eli Lilly, clearing an acquisition that expands Lilly’s biologics/pipeline footprint and signals continued M&A-driven growth. Ventyx Biosciences Shareholders Approve Merger With Eli Lilly
• Positive Sentiment: Eli Lilly says it is preparing to launch its oral obesity drug orforglipron in the U.S. as soon as Q2 if FDA approval comes — a potential multi‑billion dollar new product that’s central to revenue expectations. Eli Lilly on track to launch oral obesity drug in second quarter, pending US approval
• Positive Sentiment: CHMP has backed expanded use of Olumiant for adolescents with severe alopecia areata, moving the EU approval decision closer and potentially broadening an existing product’s market. LLY Wins CHMP Nod for Olumiant’s Expanded Use in Alopecia Areata
• Positive Sentiment: Lilly advanced remternetug clinical testing in China for Alzheimer’s, extending its geographic and therapeutic reach in neuroscience — positive for long‑term pipeline value in a high‑need area. Lilly Advances Remternetug Testing in China, Extending Its Alzheimer’s Pipeline Reach
• Positive Sentiment: Lilly reported a Phase 1 update advancing a new oral diabetes candidate in China — further international development that could support future launches and address diabetes market demand. Eli Lilly Advances New Oral Diabetes Drug In China: What Investors Should Watch
• Neutral Sentiment: Coverage and commentary (Zacks/Yahoo/analysis pieces) highlight strong recent gains but warn momentum has cooled and valuation is rich — important context for near‑term trader flows and analyst expectations. Eli Lilly and Company (LLY) is Attracting Investor Attention: Here is What You Should Know
• Negative Sentiment: Competitor risk: Novo Nordisk is expanding manufacturing in Ireland to strengthen oral GLP-1 supply — a move that could intensify competition in the obesity/diabetes market where Lilly is targeting major growth. Why Novo Nordisk’s Ireland expansion is key to fighting off Eli Lilly
• Negative Sentiment: Some retail/analyst commentary argues investors should consider other large-cap pharma names instead of Lilly given valuation and competition — adds short‑term negative sentiment even if longer‑term thesis stays intact. Should You Forget Eli Lilly and Buy These Unstoppable Stocks Instead?

Eli Lilly and Company Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.